Skip to main content
. Author manuscript; available in PMC: 2016 Apr 20.
Published in final edited form as: Nature. 2015 Apr 22;520(7549):692–696. doi: 10.1038/nature14426

Figure 2. Efficient tumour control and survival benefit in B16F10 melanoma with an RNA vaccine encoding a single mutated CD4+ T-cell epitope.

Figure 2

a, Tumour growth (mean + s.e.m.) and survival (±CD4- or CD8-depleting antibodies) in untreated (control) or B16-M30 immunized C57BL/6 mice (n = 10) inoculated subcutaneously (s.c.) with B16F10. b, B6 albino mice (n = 8) developing lung metastases upon intravenous (i.v.) injection of B16F10-Luc were treated with B16-M30 or irrelevant RNA (control). Median tumour growth was determined by BLI as photons per second. c, Single-cell suspensions of B16F10 tumours of irrelevant (control) or B16-M30 RNA immunized mice (n = 4) were restimulated with B16-M30 or irrelevant peptide (vesicular stomatitis virus nucleoprotein, VSV-NP52–59) and tested by ELISpot (mean + s.e.m.). Data pooled from two experiments. d, Frequency of infiltrating cells in s.c. B16F10 tumours (n = 3) left untreated (control) or vaccinated with B16-M30 RNA.